Tenaya Therapeutics, Inc. (TNYA)
Health Care · Genetic medicines / cardiac gene therapy · Nasdaq
A precision-medicine gene therapy company targeting the genetic root causes of heart disease with AAV-delivered therapies and small-molecule programs.
What Tenaya Therapeutics, Inc. does
Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering precision medicine therapies that address the underlying genetic causes of heart disease. The company is advancing three clinical-stage candidates: TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy; and TN-301, a small molecule HDAC6 inhibitor for heart failure and other cardiac conditions. Tenaya combines proprietary drug discovery capabilities anchored in human genetics with internal expertise in AAV gene therapy development and manufacturing.
Themes: ["Gene therapy / genetic medicines","Precision medicine / genetic heart disease","Hypertrophic cardiomyopathy (HCM)","Arrhythmogenic right ventricular cardiomyopathy (ARVC)","Heart failure with preserved ejection fraction (HFpEF)","Duchenne muscular dystrophy (DMD)","Pulmonary arterial hypertension (PAH)"]
Fundamentals
- Price$0.87 as of 2026-07-10 close
- Market cap$189M as of 2026-07-13
- 1-year return+26.5% as of 2026-07-10 close
- ROE-80.6% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Beta2.86 as of 2026-07-13
Key risks (from latest filing)
["Gene therapy candidates TN-201 and TN-401 are in early Phase 1b/2 clinical testing; there is no guarantee of positive efficacy or safety data or regulatory approval","Dependence on third parties for preclinical and clinical trial execution and manufacturing of product candidates","Significant intellectual property risk; protection scope and patent term extensions for cardiovascular genetic medicines remain uncertain, and third-party IP infringement claims could impede product development"]
Competitors & peers
- Sesen Bio (SESN)
- Audentes Therapeutics (acquired by Astellas)
- Regenxbio Inc. (RGNX)
- Solid Biosciences (SLDB)
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.